Trial Profile
Phase 1, Double-Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Two-Stage, Comparative Pharmacokinetic Study of EirGenix' Trastuzumab and Herceptin® (Trastuzumab) Sourced From US and EU Administered to Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Oct 2023
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer
- Focus Pharmacokinetics
- Sponsors EirGenix
- 03 Oct 2023 Primary endpoint (Area under the concentration/time curve, from time 0 h extrapolated to infinity (AUC(0-))) has been met, according to an European Medicines Agency.
- 15 May 2017 New trial record
- 02 May 2017 According to an EirGenix media release, the trial was performed in compliance with EMA and FDA biosimilar regulations.